JP2016501528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501528A5 JP2016501528A5 JP2015546782A JP2015546782A JP2016501528A5 JP 2016501528 A5 JP2016501528 A5 JP 2016501528A5 JP 2015546782 A JP2015546782 A JP 2015546782A JP 2015546782 A JP2015546782 A JP 2015546782A JP 2016501528 A5 JP2016501528 A5 JP 2016501528A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- viral particle
- protein
- isolated viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 30
- 230000003612 virological effect Effects 0.000 claims 24
- 230000000295 complement effect Effects 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 241000700605 Viruses Species 0.000 claims 10
- 230000004888 barrier function Effects 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 8
- 210000004556 brain Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 108700026244 Open Reading Frames Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 238000007917 intracranial administration Methods 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 4
- 239000002299 complementary DNA Substances 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 230000007402 cytotoxic response Effects 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000008827 biological function Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2012/050893 WO2014089668A1 (en) | 2012-12-12 | 2012-12-12 | Compositions and methods for the treatment of brain cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501528A JP2016501528A (ja) | 2016-01-21 |
| JP2016501528A5 true JP2016501528A5 (cg-RX-API-DMAC7.html) | 2016-03-03 |
| JP6162818B2 JP6162818B2 (ja) | 2017-07-12 |
Family
ID=50933623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546782A Active JP6162818B2 (ja) | 2012-12-12 | 2012-12-12 | 脳癌の治療のための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150307559A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2931880B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6162818B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105008524A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012396787B9 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015013669A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2894618A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL239374B (cg-RX-API-DMAC7.html) |
| MX (1) | MX366493B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2705244C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014089668A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070440A2 (en) | 2009-12-10 | 2011-06-16 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| EP2718427B1 (en) | 2011-06-08 | 2017-01-11 | Children's Hospital of Eastern Ontario Research Institute Inc. | Compositions for glioblastoma treatment |
| EP3622965A1 (en) | 2013-02-21 | 2020-03-18 | Turnstone Limited Partnership | Vaccine composition |
| EP3624825A4 (en) * | 2017-05-19 | 2021-03-10 | Georgia State University Research Foundation, Inc. | RECOMBINANT ONCOLYTIC VIRUS |
| JP2020534007A (ja) | 2017-09-22 | 2020-11-26 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック | 変異型ウイルスタンパク質 |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| US12440564B2 (en) | 2023-09-25 | 2025-10-14 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004524813A (ja) * | 2000-09-22 | 2004-08-19 | バイレクシス コーポレイション | 改良された条件付けで複製するベクター類、それらの生成及び使用方法 |
| ES2741138T3 (es) * | 2006-09-15 | 2020-02-10 | Childrens Hospital Of Eastern Ontario Res Institute Inc | Rhabdovirus oncolítico de Farmington |
| DE102008050860A1 (de) | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
-
2012
- 2012-12-12 MX MX2015007093A patent/MX366493B/es active IP Right Grant
- 2012-12-12 CN CN201280077698.6A patent/CN105008524A/zh active Pending
- 2012-12-12 CA CA2894618A patent/CA2894618A1/en not_active Abandoned
- 2012-12-12 WO PCT/CA2012/050893 patent/WO2014089668A1/en not_active Ceased
- 2012-12-12 RU RU2015128078A patent/RU2705244C2/ru active
- 2012-12-12 EP EP12889818.6A patent/EP2931880B1/en not_active Not-in-force
- 2012-12-12 JP JP2015546782A patent/JP6162818B2/ja active Active
- 2012-12-12 BR BR112015013669A patent/BR112015013669A2/pt not_active Application Discontinuation
- 2012-12-12 AU AU2012396787A patent/AU2012396787B9/en not_active Ceased
- 2012-12-12 US US14/651,761 patent/US20150307559A1/en not_active Abandoned
-
2015
- 2015-06-11 IL IL239374A patent/IL239374B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501528A5 (cg-RX-API-DMAC7.html) | ||
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| RU2015128078A (ru) | Композиции и способы лечения рака мозга | |
| Choi et al. | Polymeric oncolytic adenovirus for cancer gene therapy | |
| JP2015518818A5 (cg-RX-API-DMAC7.html) | ||
| JP2014512171A5 (cg-RX-API-DMAC7.html) | ||
| JP2017031213A5 (cg-RX-API-DMAC7.html) | ||
| JP2013067645A5 (cg-RX-API-DMAC7.html) | ||
| JP2012530715A5 (cg-RX-API-DMAC7.html) | ||
| JP2015514115A5 (cg-RX-API-DMAC7.html) | ||
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| JP2014530873A5 (cg-RX-API-DMAC7.html) | ||
| JP2013541583A5 (cg-RX-API-DMAC7.html) | ||
| JP2019531293A5 (cg-RX-API-DMAC7.html) | ||
| SI2823048T1 (en) | A new drug delivery system based on JCV-VLP | |
| CN111905101B (zh) | 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法 | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2014530246A5 (cg-RX-API-DMAC7.html) | ||
| JP2017502058A5 (cg-RX-API-DMAC7.html) | ||
| JP2012517459A5 (cg-RX-API-DMAC7.html) | ||
| Maseda et al. | Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit | |
| WO2013130672A3 (en) | Improved cancer treatments and diagnostics | |
| Hegde et al. | To market, to market—2008 | |
| JP2014506563A5 (cg-RX-API-DMAC7.html) | ||
| JP2013523789A5 (cg-RX-API-DMAC7.html) |